MedTrace Logo

The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

NCT06158945 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-12-06

No results posted yet for this study

Summary

Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD

Conditions

Interventions

DIAGNOSTIC_TEST

urinary endothelin 1

assesment of endothelin 1 in urinary sample

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2024-10-23
Completion
2024-10-23

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06158945 on ClinicalTrials.gov